Table 2.
Analyte Positivec | ART experienced,b analyte negative | ART naïveb | Total | |||||
---|---|---|---|---|---|---|---|---|
Percent | 95% CI | Percent | 95% CI | Percent | 95% CI | Percent | 95% CI | |
Genotype result | wgt na = 2643 | wgt na = 677 | wgt na = 4623 | wgt na = 7943 | ||||
No resistance | 24.4 | 14.4–38.3 | 49.0 | 10.7–88.4 | 72.6 | 55.2–85.1 | 54.6 | 43.4–65.4 |
Any resistance | 21.3 | 9.1–42.4 | 51.1 | 11.6–89.3 | 6.3 | 2.4–15.5 | 15.1 | 8.2–26.3 |
Genotyping failure | 54.3 | 35.4–72.0 | 0.0 | – | 21.1 | 9.4–40.7 | 30.3 | 20.3–42.6 |
Resistance - among those genotyped | wgt na = 1209 | wgt na = 677 | wgt na = 3650 | wgt na = 5536 | ||||
No resistance | 53.4 | 30.0–75.7 | 49.0 | 10.7–88.4 | 92.0 | 81.0–96.9 | 78.3 | 64.3–87.9 |
Any resistance | 46.6 | 24.6–70.0 | 51.1 | 11.6–89.3 | 8.0 | 3.1–18.9 | 21.7 | 12.1–35.7 |
Drug class resistance | wgt na = 564 | wgt na = 346 | wgt na = 291 | wgt na = 1201 | ||||
Single class | ||||||||
NRTI only | 0.0 | – | 0.0 | – | 0.0 | – | 0.0 | – |
NNRTI only | 0.0 | – | 73.1 | 27.9–95.0 | 63.0 | 18.1–92.9 | 36.3 | 17.7–60.2 |
PI only | 0.0 | – | 12.2 | 1.4–58.6 | 11.5 | 1.2–58.0 | 6.3 | 1.3–25.7 |
Dual class | ||||||||
NRTI/NNRTI | 100.0 | – | 14.7 | 1.6–64.1 | 0.0 | – | 51.2 | 28.3–73.6 |
PI/NRTI | 0.0 | – | 0.0 | – | 25.5 | 3.3–77.6 | 6.2 | 0.7–37.3 |
PI/NNRTI | 0.0 | – | 0.0 | – | 0.0 | – | 0.0 | – |
aWeights account for sampling, non-response, and age/sex of target population, bBy self report, c Assessed EFV, LPV, NVP